title: How should we assess the value of innovative drugs in oncology? Lessons from cost-effectiveness analyses.
authors: Medical Oncology Service, National Cancer Institute, National Institutes of Health, Bethesda, MD Hematology-Oncology Service, Knight Cancer Center, Oregon Health & Sciences University, Portland, OR.
authors: Vinay
authors: http://orcid.org/0000-0002-6110-8221
authors: V
authors: Prasad
authors: Medical Oncology Service, National Cancer Institute, National Institutes of Health, Bethesda, MD Myeloma Service, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY.
authors: Sham
authors: S
authors: Mailankody
mesh_terms: D000970:Antineoplastic Agents / Q000191:economics*; D019337:Hematologic Neoplasms / Q000191:economics* / Q000628:therapy*; D006801:Humans; D011788:Quality of Life; D019057:Quality-Adjusted Life Years
chemical_list: D000970:Antineoplastic Agents